Valneva SE

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. Its main products include IXIARO, an inactivated Japanese encephalitis vaccine; DUKORAL, an oral vaccine for diarrhea caused by Vibrio cholerae or enterotoxigenic E. coli; and IXCHIQ/VLA1553, a single-dose live-attenuated vaccine for chikungunya. The company also has a pipeline of vaccine candidates, such as VLA15 against Lyme disease, S4V2 against shigellosis, VLA1601 against Zika virus, VLA1554 against human metapneumovirus, VLA84 against Clostridium difficile infection, and VLA2112 against Epstein-Barr virus. Valneva sells its products globally.

Valneva SE is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol VALN. Its shares trade in US dollars (USD). The company is based in France and its primary listing is on Nasdaq, making it accessible to US and international investors. The use of USD as the trading currency facilitates investment from North American markets.

Valneva SE operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, Valneva focuses on the research, development, and commercialization of vaccines. Biotechnology firms like Valneva use biological processes and living organisms to create medical solutions, and in this case, the company specializes in prophylactic vaccines that prevent infectious diseases. The industry is characterized by high research and development costs, regulatory hurdles, and the potential for significant impact on public health.

Valneva SE is headquartered in Saint-Herblain, France, and was founded in 1998. The company sells its products globally, indicating a broad market reach that includes multiple countries and regions. Its vaccines are distributed worldwide, addressing infectious diseases that affect populations across different continents. While the company is based in Europe, its products are used internationally, and its listing on a US exchange further underscores its global presence.

Valneva SE generates revenue by developing, manufacturing, and commercializing prophylactic vaccines. The company sells its approved vaccines, such as IXIARO, DUKORAL, and IXCHIQ, directly to healthcare providers, governments, and international organizations. Additionally, Valneva has a pipeline of vaccine candidates in various stages of development, which may generate future revenue through licensing agreements, partnerships, or direct sales upon approval. The company's business model relies on continuous R&D investment to address unmet medical needs and expand its product portfolio, thereby creating long-term value through innovation and global commercialization.